Aubagio®
Quick Facts
Aubagio® is an immunomodulatory disease-modifying therapy that helps support the immune system.
Oral tablet
7mg or 14mg, daily
Relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS
Potential Benefit:
- 7 mg showed a 22% reduction in relapses compared with placebo.
- 14 mg showed a 36% reduction in relapses compared with placebo.
- 7 mg showed a 33% reduction in total lesion volume.
- 14 mg showed 67% reduction in total lesion volume.
- Aubagio was shown to be effective vs. placebo in two of the three key measures—relapses and brain lesions—but not disability progression.
Common Potential Side Effects
Hair thinning, diarrhea, headache.
Prescription Assistance:
For assistance finding additional resources that might help cover the costs of your prescription, contact MSAA.
DRUGMAKER
Sanofi
HOW Aubagio® WORKS
Aubagio®, a tablet taken once per day by mouth, is an immunomodulator. MS relapses are triggered by overactive immune cells. Aubagio® blocks an enzyme necessary for the growth of these overactive immune cells. By blocking this enzyme, there are less of these cells to damage in the brain and spine.
FDA-Approved
Aubagio® was FDA-approved in 2012. It is approved to treat relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Potential Side Effects
Headache, elevations in liver enzymes, hair thinning, diarrhea, nausea, neutropenia (a condition that reduces the number of certain white blood cells), and paresthesia (tingling, burning, or numbing sensation). More severe adverse events include the risk of severe liver injury, hypertension and risk of fetal harm.
OTHER KEY INFORMATION
Labs completed prior to starting Aubagio® include:
- Cell count
- Liver function tests
- Tuberculosis test
Labs after starting Aubagio® include:
- Monthly liver function tests for the first six months
- Your clinician will likely order cell count and liver function tests every six months after that